GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...
3d
Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...
TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.
Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...
Cosentyx, Entresto, Kesimpta, Pluvicto, Scemblix, Zolgensma, Kisqali and Leqvio should fuel growth through 2030 and beyond. NVS is a Zacks Rank #2 (Buy) stock, with a Value Style Score of B and VGM ...
Novartis hat auch im dritten Quartal Umsatz und Ergebnis deutlich gesteigert. Somit kann das Basler Unternehmen seine ...
Am Dienstag nahm TD Cowen die Aktien von TG Therapeutics (NASDAQ:TGTX) unter Beobachtung und vergab eine Kaufempfehlung mit einem Kursziel von 50,00 US-Dollar. Die Analyse stützt sich auf das Potenzia ...
Der Schweizer Pharmakonzern erhöht abermals seine Finanzziele für dieses Jahr. Die Konzentration auf vier Kerngebiete zahle sich aus, sagt der Konzernchef.
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...
On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...
TD Cowen analyst Tara Bancroft initiated coverage of TG Therapeutics (TGTX) with a Buy rating and $50 price target The company’s Briumvi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback